太阳集团见好就收9728(中国)有限公司

  • Home
  • Respect Talents
    1. Office Env
    2. Promotion Space
    3. Personnel Policy
    4. Entry Notice
    5. Benefits
    6. Job Demand

    Respect Talents

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • About Us
    1. Company Profile
    2. Company History
    3. Affiliation Structure

    About Us

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • Registration Declaration
    1. Import Registration
    2. Approved Varieties
    3. Related Varieties
    4. Variety in report
    5. Species to be reported
    6. Declared varieties

    Registration Declaration

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • R & D field
    1. R&D Catalog
    2. Psychotropic Drugs
    3. Medicinal chemistry
    4. Chemical Synthesis
    5. Chemical Analysis
    6. Pharmaceutical Preparations
    7. Pharmacological Research
    8. Drug Toxicology

    R & D field

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • R&D Equipment
    1. Equipment
    2. Laboratory

    R&D Equipment

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • News
    1. Company News
    2. Industry News
    3. Latest Announcement

    News

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • External Information

    External Information

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

  • Contact Us

    Contact Us

    VAYUAN focuses on drug synthesis, formulations, quality analysis, drug packaging compatibility research, microbiology, standard physical and chemical testing, drug registration and application, and other comprehensive drug development and drug clinical trial research.

The State Council’s major documents may affect all pharmaceutical companies

Time:2021-12-16 Views:327

Recently, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council issued the "Action Plan for Building a High Standard Market System."

The "Action Plan" starts with the most prominent links and areas that restrict the development of the market system, the most urgent feedback from the masses, the most concerned by all walks of life, and the weakest market supervision. , A high-standard market system with complete systems and perfect governance", put forward 51 specific measures around five aspects including basic systems, factor markets, environmental quality, market opening, and market supervision to promote the implementation of actions and achieve results.

Among them, a number of contents involve the field of the pharmaceutical industry, and the details are as follows:

Strengthen the protection of intellectual property rights. Promote the implementation of regulations on several issues concerning the application of law in the trial of civil cases of infringement of trade secrets, and issue regulations on issues concerning the application of law in the trial of civil cases involving drug marketing review, review and approval of patents. Research and formulate rules for the protection of intellectual property rights in the field of drug patent protection and cross-border e-commerce, and formulate and publish guidelines for corporate intellectual property protection and country-specific guidelines for intellectual property protection.

Strengthen and improve anti-monopoly and anti-unfair competition law enforcement. Resolutely oppose monopoly and unfair competition. Formulate anti-monopoly guidelines and guidelines for the application of exemption systems in specific areas such as APIs, and issue guidelines for the implementation of overseas anti-monopoly compliance for enterprises. Promote the improvement of legal regulations on platform enterprise monopoly identification, data collection and use management, and consumer rights protection. Strengthen anti-monopoly and anti-unfair competition regulations in new business fields such as platform economy and sharing economy. Improve the list system of charges related to enterprises, and severely investigate and punish violations of charges related to enterprises.

Vigorously promote credit classification and classification supervision. Promote the in-depth implementation of credit classification and classification supervision in more key areas such as taxation management, import and export, ecological environmental protection, medical security, and medical recruitment, and adopt differentiated supervision measures based on the credit status of the supervision objects to provide market entities with more precise and convenient services.

Guide the healthy development of platform enterprises. Support the innovation and development of platform enterprises and enhance their international competitiveness. Implement network infrastructure transformation and upgrading projects such as education, medical care, express logistics, and promote the development of new service platforms such as Internet medical care, online education, third-party logistics, instant delivery, online office, and online services, and effectively leverage the optimization of platform enterprises in the configuration of elements Integrated role. Unblock market data information flow, integrate online and offline payment transaction data, and promote cross-departmental sharing. Standardize the development of the platform economy in accordance with the law, and strengthen the supervision of platform enterprises.

Expand the opening up of the social service industry market in an orderly manner. Focus on medical, education, sports, childcare, environmental protection, municipal administration and other fields, reduce market access restrictions, and remove unreasonable restrictions on for-profit medical and educational institutions in licensing and equipment purchases. Improve the planning methods for the establishment of medical institutions, implement guiding plans for social medical institutions, and strengthen services for social capital investment medical institutions.

Judging from the above points, including strengthening the protection of pharmaceutical patents, strengthening anti-monopoly of raw materials, implementing credit supervision on pharmaceutical recruitment, and promoting the development of Internet medical services, all are very important measures to promote the development of the pharmaceutical industry.

As we all know, there can be no medical innovation without intellectual property protection. Intellectual property protection in my country plays a very important role in encouraging medical innovation. The fourth revision of the "Patent Law" was reviewed and approved in October 2020, and will come into effect on June 1, 2021.

It is reported that the new "Patent Law" adds an early settlement mechanism for drug patent disputes in the protection of intellectual property rights of innovative drugs, and for the first time proposed a new drug patent term compensation system at the legislative level. This time the country re-issued a document focusing on the protection of pharmaceutical patents. It is believed that the system and mechanism for patent protection of pharmaceuticals will continue to be improved in the future to further promote the development of my country's new drug R&D innovation.

The monopoly of APIs has also been the focus of the national market supervision department in recent years. In recent years, due to the monopolized price increase of raw materials, the prices of preparations have soared, stocks are out of stock, and stocks are out of stock. Many provinces have issued notices saying that the shortage of medicines is out of stock. The reason is that the price of raw materials has risen, resulting in the inability to guarantee the supply of products. Under severe investigations, the State Administration of Markets has issued huge fines to many pharmaceutical companies suspected of monopoly of APIs.

In addition, the policy level has continuously improved the anti-monopoly of APIs. Following the 2017 National Development and Reform Commission’s "Guidelines for the Price Behavior of Short Drugs and API Operators", on October 13, 2020, the State Administration for Market Regulation issued the "Anti-monopoly Guidelines in the Field of APIs (Draft for Solicitation of Comments) )". The "Guide" provides very detailed definitions and regulations on monopolistic violations in the field of APIs, which are intended to promote the healthy development of the API industry, maintain the order of market competition in the API field, protect consumer interests and social public interests, and prevent and stop them. Monopoly in the field of APIs.

With the introduction of the "Action Plan for Building a High Standard Market System", it will promote the healthy development of the capital market and develop knowledge, technology and data element markets. The pharmaceutical industry with innovation as its core driving force is also ushering in a new stage of development.

Next Previous

Qingdao Vayuan Pharmaceutical Technology Ltd.

TEL:0532-55678600

Fax:0532-55678586

Email:ad@vayuan.com

Time:Monday to Friday 8:30~12:00; 13:00~17:30

Address:11th Floor, No.377 Nanjing Rd. Qingdao City, Shandong Province, China

Telephone

+86-0532-55678600

Copyright © 2018-2020 Qingdao Vayuan Pharmaceutical Technology Ltd. All Rights Reserved. 备案号:鲁ICP备20020049号

XML 地图 | Sitemap 地图